Search
The Newsletter
The Principals
Reports
Conferences
Databases
Custom Research
Contact Us
Home
 

Online Report Subscribers, Click Here

Pricing and Ordering Information

 

Women's Health: Trends and Opportunities in the U.S. Osteoporosis Management Market
Report #A331
- September 2013
150 Pages – 37 Exhibits – 8 Company Profiles


In the United States (U.S.), the rate of osteoporosis is expected to grow significantly as the population ages. It is estimated that approximately 9 million adults in the U.S. have osteoporosis and more than 48 million have low bone mass, placing them at risk for developing osteoporosis. Assuming that prevalence of osteoporosis and low bone mass remains unchanged, by the year 2020, it is projected that 10.7 million adults in the U.S. will have osteoporosis and 58.2 million will have low bone mass.

This dynamic new report from Medtech Insight includes analyses of products, competitors, and opportunities in the U.S. market for osteoporosis diagnosis and treatment products. During the forecast period covered by this report, the U.S. market for osteoporosis management products is projected to grow to an estimated $6.4 billion by the year 2017. This market, as covered by the scope of this report, includes diagnostic products (including bone densitometry systems and bone remodeling biochemical marker tests) and current and emerging pharmaceutical treatments (including bisphosphonates, estrogen agonists/antagonists, estrogen and estrogen/progestin therapies, monoclonal antibody inhibitors, salmon calcitonin, and synthetic parathyroid hormone).

Ordering Information

Title

Report# Publication
Date
List Price

Women's Health: Trends and Opportunities in the U.S. Osteoporosis Management Market

A331

September 2013

$3,750

Order Online:
Single User only (Please call for corporate subscription pricing)
PDF Only

Print versions of Reports are available upon request for an additional fee.

Methodology

Reports are produced exclusively by Medtech Insight, through extensive primary and secondary research among the clinicians, researchers, and competitors in the marketplace, and draw upon the industry expertise of a network of industry insiders. Medtech Insight exhaustively corroborates the data as a baseline for completing forward-looking analysis and providing insight into product, technology and market evolution.

 

TABLE OF CONTENTS

 

EXECUTIVE SUMMARY

i.       Osteoporosis Incidence and Prevalence

ii.       Osteoporosis Diagnosis and Management

a.      Bone Densitometry

b.      Biochemical Markers

c.      Pharmaceutical Treatments

iii.      Market Analysis

a.      Bone Densitometry Systems

b.      Biochemical Markers

c.      Pharmaceutical Treatments

i.       Estrogen/Hormone Therapy Drugs

ii.       Osteoporosis Drugs

iv.      Methodology

 

Exhibit ES-1:    2012, Osteoporosis-Caused Fracture Incidence, by Site

Exhibit ES-2:    Osteoporosis Management Products, Combined Market Forecast, 2012-2017

Exhibit ES-3:    Bone Densitometry Systems, Market Forecast, 2012-2017

Exhibit ES-4:    Bone Remodeling Biochemical Marker Tests, Market Forecast, 2012-2017

Exhibit ES-5:    Pharmaceutical Treatments for Osteoporosis, Market Forecast, 2012-2017

Exhibit ES-6:    2012, Pharmaceutical Treatments for Osteoporosis, Sales by Product Category

 

1. OVERVIEW OF OSTEOPOROSIS

1.1 Incidence, Prevalence, and Cost

1.2 Types of Osteoporosis

1.3 Risk Factors

 

Exhibit 1-1:      Osteoporotic Bone and Normal Bone

Exhibit 1-2:      2012, Osteoporosis-Caused Fracture Incidence, by Site

Exhibit 1-3:      Osteoporosis or Low Bone Mass in Women Age 50 and Older, by Race and Ethnicity

Exhibit 1-4:      Types of Osteoporosis

Exhibit 1-5:      Leading Risk Factors for Osteoporosis

 

2. BONE DENSITOMETRY PRODUCTS MARKET

2.1 Bone Densitometry Overview

2.1.1 Dual-Energy X-Ray Absorptiometry

2.1.2 Single-Energy X-Ray Absorptiometry

2.1.3 Radiographic Absorptiometry

2.1.4 Quantitative Computed Tomography

2.1.5 Quantitative Ultrasound

2.1.6 Hospital-Based Densitometry Systems

2.1.7 Office-Based Densitometry Systems

2.1.8 Software-Based Densitometry Systems

2.2 Densitometry Products

2.2.1 BeamMed

2.2.2 CompuMed

2.2.3 CooperSurgical/The Cooper Companies

2.2.4 Furuno USA/Furuno Electric Company

2.2.5 GE Healthcare/General Electric Company

2.2.6 Hologic

2.2.7 Lone Oak Medical Technologies

2.2.8 Sectra

2.3 Reimbursement

2.4 Market Analysis

2.5 Competitive Analysis

 

Exhibit 2-1:      Comparison of Biochemical Markers and Bone Densitometry as Tools for Diagnosing and Monitoring Osteoporosis

Exhibit 2-2:      Imaging Technologies Used to Diagnose Osteoporosis

Exhibit 2-3:      2013, Selected Bone Densitometry Systems

Exhibit 2-4:      The Sunlight MiniOmni Bone Sonometer

Exhibit 2-5:      The Norland Family of Dual-Energy X-Ray Absorptiometry Systems

Exhibit 2-6:      The Lunar iDXA Dual-Energy X-Ray Absorptiometry System

Exhibit 2-7:      The Discovery Dual-Energy X-Ray Absorptiometry System

Exhibit 2-8:      The OsteoGram Radiographic Absorptiometry System

Exhibit 2-9:      The CM-200 Quantitative Ultrasound Bone Densitometry System

Exhibit 2-10:    The Accudxa2 Dual-Energy X-Ray Absorptiometry System

Exhibit 2-11:    Hospital-Based Bone Densitometry Systems, Market Forecast, 2012-2017

Exhibit 2-12:    Office-Based Bone Densitometry Systems, Market Forecast, 2012-2017

Exhibit 2-13:    Total Bone Densitometry Systems, Market Forecast, 2012-2017

Exhibit 2-14:    2012, Bone Densitometry Systems Market, Share by Supplier

 

3. BONE REMODELING BIOCHEMICAL MARKER TESTS MARKET

3.1 Biochemical Markers Overview

3.1.1 Types of Bone Turnover Markers

3.1.2 Applications

3.2 Biochemical Marker Testing Products

3.2.1 Alere

3.2.2 Beckman Coulter

3.2.3 Roche Diagnostics/Roche

3.2.4 Immunodiagnostic Systems

3.2.5 Orion Diagnostica/Orion Group

3.2.6 Quidel

3.3 Reimbursement

3.4 Market Analysis

3.5 Competitive Analysis

 

Exhibit 3-1:      The Bone Remodeling Cycle

Exhibit 3-2:      Comparison of Selected Bone Remodeling Biochemical Marker Tests

Exhibit 3-3:      2013, Selected Bone Remodeling Biochemical Marker Tests

Exhibit 3-4:      Bone Remodeling Biochemical Marker Tests, Market Forecast, 2012-2017

Exhibit 3-5:      2012, Bone Remodeling Biochemical Marker Tests Market, Share by Supplier

 

4. OSTEOPOROSIS PHARMACEUTICAL TREATMENTS MARKET

4.1 Clinical Overview

4.1.1 Antiresorptive Drugs

4.1.1.1 Bisphosphonates

4.1.1.1.1 Alendronate

4.1.1.1.2 Ibandronate

4.1.1.1.3 Risedronate

4.1.1.1.4 Zoledronate

4.1.1.2 Salmon Calcitonins

4.1.1.2.1 Novartis

4.1.1.2.2 Unigene Laboratories

4.1.1.2.3 Emerging Drugs

4.1.1.3 Estrogen/Hormone Therapy

4.1.1.4 Receptor Activator of Nuclear Factor KappaB Ligand Inhibitors

4.1.1.5 Estrogen Agonists/Antagonists

4.1.1.5.1 Emerging Drugs

4.1.1.5.1.1 Pfizer

4.1.1.5.1.2 EndoCeutics

4.1.1.6 Other Emerging Antiresorptives

4.1.1.6.1 Cathepsin K Inhibitors

4.1.1.6.2 Monoclonal Antibodies

4.1.1.6.2.1 Alethia Biotherapeutics

4.1.1.6.2.2 Novo Nordisk

4.1.2 Bone-Forming Drugs

4.1.2.1 Synthetic Parathyroid Hormone

4.1.2.1.1 Forteo

4.1.2.1.2 Pipeline Drugs

4.1.2.1.2.1 Radius Health

4.1.2.2 Other Emerging Anabolic Drugs

4.1.2.2.1 Serotonin Inhibitors

4.1.3 Bone Morphogenetic Proteins

4.1.4 Dual-Action Bone Agents

4.1.4.1 Strontium Ranelate

4.1.4.2 Strontium Malonate

4.1.5 Gene Therapy

4.2 Market Analysis

4.2.1 Estrogen/Hormone Therapy Drugs

4.2.2 Osteoporosis Drugs

4.2.2.1 Bone-Building Drugs

4.2.2.2 Bisphosphonates

4.2.2.3 Receptor Activator of Nuclear Factor KappaB Ligand Inhibitors

4.2.2.4 Salmon Calcitonin

4.3 Competitive Analysis

 

Exhibit 4-1:      2013, Selected Pharmaceutical Treatments for Osteoporosis

Exhibit 4-2:      2013, Selected Emerging Pharmaceutical Treatments for Osteoporosis

Exhibit 4-3:      Estrogen/Hormone Therapy and Osteoporosis Drugs, Market Forecast, 2012-2017

Exhibit 4-4:      2012, Estrogen/Hormone Therapy and Osteoporosis Drugs, Sales by Product Category

Exhibit 4-5:      United States Patent Status of Selected  Estrogen/Hormone Therapy Drugs

Exhibit 4-6:      United States Patent Status of Selected Osteoporosis Drugs

Exhibit 4-7:      2012, Estrogen/Hormone Therapy and Osteoporosis Drugs Market, Share by Supplier

 

5. COMPANY PROFILES

5.1       Alere, Inc.

5.2       The Cooper Companies, Inc.

5.3       GE Healthcare/General Electric Company

5.4       Hologic, Inc.

5.5       Eli Lilly and Company

5.6       Novartis AG

5.7       Pfizer, Inc.

5.8       Roche Holding AG

 

APPENDIX:  COMPANY LISTING

 

To order reports or obtain information about special pre-publication offers from within the U.S., contact custcare@informa.com. You can also call 1.908.748.1221 (or toll-free within the U.S. at 1.800.332.2181) or fax 1.908.748.1222.

 

The Newsletter | The Principals | Reports | Conferences | Physician Surveys | Consulting | Contact Us | Home